ArticleFrontiers in endocrinology2026
The correlation between blood urea nitrogen to creatinine ratio and short-term and long-term all-cause mortality in sepsis-associated acute kidney injury patients aged 50 and above: a large retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Simple Admission-Based Score for Early Mortality Risk Stratification in Non-Shock Sepsis: A Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between the blood urea nitrogen to creatinine ratio (BUN/Cr) and all-cause mortality in sepsis-associated acute kidney injury (SA-AKI) patients aged ≥ 50 years. Methods: This single-center, retrospective cohort study included 764 patients aged ≥ 50 years with SA-AKI hospitalized at Henan Provincial People's Hospital from January 2020 to August 2024. Patients were grouped into BUN/Cr tertiles: T1 (≤ 16.00), T2 (16.01-22.50), and T3 (> 22.50). The primary outcomes were 28-day, 90-day, and 1-year all-cause mortality. Associations between BUN/Cr and mortality were evaluated using Cox regression and subgroup analyses. Predictive value and dose-response relationships were assessed via receiver operating characteristic (ROC) curves and restricted cubic spline (RCS) models. Results: In the overall cohort, the all-cause mortality rates at 28 days, 90 days, and 1 year were 5.0%, 11.4%, and 22.3%, respectively. After adjusting for confounders, each 1-unit increase in BUN/Cr was linked to higher mortality at 28 days (HR = 1.039, 95% CI: 1.014-1.064), 90 days (HR = 1.038, 95% CI: 1.020-1.055), and 1 year (HR = 1.027, 95% CI: 1.013-1.041). A 1-standard deviation increase in BUN/Cr corresponded to a 45.0%, 43.6%, and 29.4% increased risk at each time point (all P < 0.05). Compared with the T1 group, patients in the T3 had significantly higher risks of 90-day (HR = 3.042, 95% CI: 1.742-5.312) and 1-year (HR = 1.971, 95% CI: 1.349-2.879) mortality. Subgroup analyses confirmed consistent associations between BUN/Cr and 90-day and 1-year mortality across various clinical subgroups. ROC curve analysis demonstrated that BUN/Cr had a moderate predictive ability for mortality at 28 days (AUC = 0.636), 90 days (AUC = 0.656), and 1 year (AUC = 0.610). Notably, adding BUN/Cr to the baseline multivariable model significantly improved discrimination for 28-day mortality (P for comparison = 0.012). RCS modeling showed a linear and positive association between BUN/Cr and mortality without significant non-linearity (P-nonlinear > 0.5 for all time points). Conclusion: A higher BUN/Cr ratio is significantly linked to increased short- and long-term mortality in SA-AKI patients aged 50 and above, suggesting its potential utility for early risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.